MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing

Moderna shares rose 3.5% after an FDA advisory panel voted 9-0 that mFlusiva’s benefits outweigh its risks for influenza prevention in older adults. The vote improves the odds of regulatory approval ahead of the Aug. 5 FDA decision. The move is supportive for Moderna’s vaccine pipeline and could lift sentiment around the stock, though final approval is still pending.

Analysis

Moderna shares rose 3.5% after an FDA advisory panel voted 9-0 that mFlusiva’s benefits outweigh its risks for influenza prevention in older adults. The vote improves the odds of regulatory approval ahead of the Aug. 5 FDA decision. The move is supportive for Moderna’s vaccine pipeline and could lift sentiment around the stock, though final approval is still pending.